Clinical and pharmacological group: & nbsp

Regulators of water-electrolyte balance and KHS

Included in the formulation
  • Trisol
    solution in / in 
  • Trisol
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Trisol
    solution in / in 
  • АТХ:

    B.05.B.B   Solutions affecting the water-electrolyte balance

    B.05.B.B.01   Electrolytes

    Pharmacodynamics:

    Reduces hypovolemia, increases diuresis, reduces blood thickening and metabolic acidosis, improves capillary circulation, exerts detoxification effect. Plasma-substituting agent.

    Pharmacokinetics:

    Not studied. Excretion by the kidneys (potassium ions - in the distal tubules in exchange for sodium or hydrogen ions), a small amount is excreted with sweat.

    Indications:Diseases associated with dehydration and intoxication of the body (including acute dysentery, food poisoning, cholera El Tor (Inaba)).

    I.A00-A09.A00   Cholera

    I.A00-A09.A03.9   Shigellosis, unspecified

    I.A00-A09.A03.8   Other shigellosis

    I.A00-A09.A03.3   Shigellosis caused by Shigella sonnei

    I.A00-A09.A03.2   Shigellosis caused by Shigella boydii

    I.A00-A09.A03.1   Shigellosis caused by Shigella flexneri

    I.A00-A09.A03.0   Shigellosis caused by Shigella dysenteriae

    I.A00-A09.A05   Other bacterial food poisoning

    I.A00-A09.A08   Viral and other specified intestinal infections

    I.A00-A09.A09   Diarrhea and gastroenteritis of allegedly infectious origin

    Contraindications:

    Hypersensitivity, hyperkalemia, alkalosis, the presence of contraindications to the introduction of large amounts of fluid in the body, renal failure, chronic heart failure.

    Carefully:

    With arterial hypertension, edema, anuria or oliguria, conditions that have hyperkalaemia.

    Pregnancy and lactation:

    No information.

    Category of recommendations FDA for the combination is not defined. Category of recommendations FDA for sodium bicarbonate - C.

    Dosing and Administration:

    Intravenously (drip and drop) under the control of laboratory indicators. In severe forms of diseases (hypovolemic infectious-toxic shock, decompensated metabolic acidosis, anuria) begin with a jet injection of the drug followed by a transition to a drop.

    With lighter forms of diseases (intoxication and dehydration of the body, metabolic acidosis, oliguria), it can be limited to drip administration of the drug.

    The total amount of solution introduced should correspond to the volume of the liquid lost.

    The ratio of the injected fluid and diuresis is determined every 6 hours. Within 1 hour, the solution is administered in an amount corresponding to 7-10% of the body weight of the patient; then the jet infusion is replaced by a dropwise addition, for 24-48 hours, at a rate of 40-120 drops per minute.

    Side effects:

    Edema, tachycardia, rarely - chills.

    Overdose:

    Not described.

    Interaction:

    Not described.

    Special instructions:

    In the case of hyperkalemia, it is necessary to replace the drug with a solution of sodium acetate / sodium chloride until the electrolyte balance is normalized. Before injection, the solution is heated to 36-38 ° C.

    Instructions
    Up